Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Spruce Biosciences, Inc. SPRB
$2.18
-$0.08 (-3.54%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
91416030.00000000
-
week52high
3.57
-
week52low
0.96
-
Revenue
0
-
P/E TTM
-1
-
Beta
2.30931700
-
EPS
-1.97000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 16 мар 2022 г. |
| RBC Capital | Outperform | Outperform | 15 мар 2022 г. |
| Ladenburg Thalmann | Buy | 08 мар 2022 г. | |
| Oppenheimer | Outperform | 17 дек 2021 г. | |
| Benchmark | Speculative Buy | 10 дек 2021 г. | |
| Oppenheimer | Outperform | Outperform | 17 ноя 2022 г. |
| JMP Securities | Market Outperform | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gharib Samir M. | D | 225000 | 37500 | 03 янв 2023 г. |
| Gharib Samir M. | D | 55818 | 15293 | 03 янв 2023 г. |
| Gharib Samir M. | A | 71111 | 37500 | 03 янв 2023 г. |
| Szwarcberg Javier B. | A | 14705 | 14705 | 30 дек 2022 г. |
| Charlton Ralph William III | A | 12864 | 12864 | 30 дек 2022 г. |
| Gharib Samir M. | A | 33611 | 1 | 30 дек 2022 г. |
| Charlton Ralph William III | A | 127000 | 127000 | 05 дек 2022 г. |
| Szwarcberg Javier B. | A | 444000 | 444000 | 05 дек 2022 г. |
| Gharib Samir M. | A | 149000 | 149000 | 05 дек 2022 г. |
| Gharib Samir M. | D | 262500 | 37500 | 30 июн 2022 г. |
Новостная лента
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Business Wire
30 авг 2022 г. в 16:05
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference